Results 121 to 130 of about 5,926 (192)

Tracking DNA damage localization and chromatin remodeling in live cells using time-resolved quantitative analysis of DNA counterstains. [PDF]

Cell Mol Life Sci
Paternò G, Longo E, Lanzanò L.
europepmc   +1 more source

A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer. [PDF]

Cancer
Miller KD, Thomas A, Althouse S, Zang Y, Conder E, Burgos R, Schneider BP, Ballinger T, Douglas E, Ansley K, Jang HJ, Chung W, Issa JP, Nephew KP, Rassool FV.   +14 more
europepmc   +1 more source

PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma. [PDF]

Cancer Cell Int
Juli G, Ronchetti D, Signorelli S, Squillacioti S, Polerà N, Maienza A, Vocaturo M, Galvano A, Taiana E, Tagliaferri P, Tassone P, Caracciolo D.   +11 more
europepmc   +1 more source

Clinicopathological and functional evaluation of replication protein A in epithelial ovarian cancers: A target validation study. [PDF]

Transl Oncol
Algethami M, Sheha A, Singhania N, Alqahtani S, Shoqafi A, Tosun Ç, Spicer J, Toss MS, Alblihy A, Lashen A, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S.   +13 more
europepmc   +1 more source

A Design of Experiments-Based Chiral HPLC Method for the Quantification of Talazoparib and Enantiomeric Purity Determination in Pharmaceutical Formulations. [PDF]

Chirality
Atila Karaca S, Aliyeva S, Yeniceli D.
europepmc   +1 more source

Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition. [PDF]

PLoS One
Chapman IG, Wu X, Veuger S, Jowsey PA.
europepmc   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer. [PDF]

J Clin Pharmacol
Hadigol M, Williams JH, Shi H, Yang DZ, Hoffman J, Wang DD.   +5 more
europepmc   +1 more source

Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model-Informed Drug Development in Approval Despite Failed Bioequivalence. [PDF]

CPT Pharmacometrics Syst Pharmacol
Wang D, Guo CC, Gao X, Wang Y, Yu Y, Plotka A, Elmeliegy M, Shi H, Johnson S, DeAnnuntis L, Hoffman J.   +10 more
europepmc   +1 more source

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source

Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. [PDF]

Cancer Res
Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, Diamond JR, Sikora MJ.   +15 more
europepmc   +1 more source